Disclosures for "Chronic Granulomatous Herpes Simplex Virus Encephalitis: A Distinct but Rare Disease "
-
Dr. Yong has nothing to disclose.
-
Dr. Turner has nothing to disclose.
-
Dr. Kapadia has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics/Amgen.
-
Prof. Jadavji has nothing to disclose.
-
Dr. Murguía-Favela has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Encoded Therapeutics. Dr. Murguía-Favela has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenxbio. Dr. Murguía-Favela has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Murguía-Favela has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BioCryst. Dr. Murguía-Favela has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Murguía-Favela has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Grifols. Dr. Murguía-Favela has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Valeo Pharma. The institution of Dr. Murguía-Favela has received research support from Jeffrey Modell Foundation. An immediate family member of Dr. Murguía-Favela has received personal compensation in the range of $500-$4,999 for serving as a Member of Clinical Panel with Canada Drug's Agency.